Showing 2401-2410 of 3318 results for "".
- Dr. Reddy's Sernivo Officially Debuts at NYC Media Eventhttps://practicaldermatology.com/news/dr-reddys-sernivo-officially-debuts-at-nyc-event/2458473/Calling Sernivo (betamethasone dipropionate) Spray 0.05% a ‘trifecta’ for dermatologists who treat mild-to-moderate psoriasis, Josh Zeichner, MD, introduced members of the New York City media to the new spray-on steroid. “It is effe
- The Osteopathic Dermatologist: Dr. Peter Ilowite Shares His Crafthttps://practicaldermatology.com/news/the-osteopathic-dermatologist-dr-peter-ilowite-shares-his-craft/2458866/Peter Ilowite, DO, Assistant Professor of Dermatology at Mt. Sinai Hospital and Dermatology Residency and an Assistant Professor of Medicine at Touro College of Osteopathic Medicine, both of New York City, spoke at the Atlantic Regional Osteopathic Convention (AROC
- Dr. Zein Obagi's New Book Presents the Art and Science of Skin Healthhttps://practicaldermatology.com/news/dr-zein-obagis-new-book-present-the-art-and-science-of-skin-health/2459023/Zein Obagi, MD, founder of ZO Skin Health, Inc., has published a new book, The Art of Skin Health Restoration and Rejuvenation: The Science of Clinical Practice, Second Edition (CRC Press, Dec 2014). In it, he reveals the Zein Ob
- Lithera Announces Appointment of Dr. Lincoln Krochmal as Chief Medical Officerhttps://practicaldermatology.com/news/20131121-lithera_announces_appointment_of_dr_lincoln_krochmal_as_chief_medical_officer/2459407/Lincoln Krochmal, MD was recently appointed as Chief Medical Officer of Lithera, Inc. According to the company, this appointment reflects the company's continued growth as it prepares to enter la
- Practical Dermatology® Magazine Launches Daily Coverage of Denver Annual Meetinghttps://practicaldermatology.com/news/20140324-practical_dermatology_magazine_launches_daily_coverage_of_denver_annual_meeting/2459297/Bryn Mawr Communications III, LLC's Practical Dermatology® magazine and DermTube.com this weekend launched daily video coverage of the Annual Meeting in Denver with host Joel L. Cohen, MD, FAAD. Dr. Cohen,
- Dr. Susan Weinkle Honored with Outstanding Educator & Mentor in Dermatology Award at ODAChttps://practicaldermatology.com/news/dr-susan-weinkle-honored-with-outstanding-educator-mentor-in-dermatology-award-at-odac/2460259/Susan H. Weinkle, MD, was awarded the Outstanding Educator & Mentor in Dermatology Award by the ODAC Dermatology, Aesthetic & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD), at the conference held January 17-20 in Orlando, FL. The award
- CPP Launches Network of Physician-led Medical Aesthetics Clinics Across UShttps://practicaldermatology.com/news/cpp-launches-network-of-physician-led-medical-aesthetics-clinics-across-us/2461442/Cosmetic Physician Partners Inc. ("CPP") is pleased to announce its official launch in the US with the closing of its 10th medical aesthetics clinic. Led by Dr. A. Jay Burns, Dr. Joel L. Cohen, Matt and Kathy Taranto and Dan Schacter, CPP is a partnership designed to provide physician o
- ASDSA Names 2022 Patient Safety Hero Awardeeshttps://practicaldermatology.com/news/asdsa-names-2022-patient-safety-hero-awardees/2461379/Mathew Avram, MD, JD and Joel Cohen, MD received the
- Dr. Raj Chovatiya: Lebrikizumab Long-Term Data Makes 'Night and Day' Differencehttps://practicaldermatology.com/news/Dr-Raj-Chovatiya-Lebrikizumab-Long-Term-Data-Makes-Night-Day-Difference/2471865/New long-term results presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showed complete skin clearance (EASI-100 or IGA 0) at 3 years in patients with moderate-to-severe atopic dermatitis taking lebrikizumab (EBGLYSS™, Eli Lilly and Company) in the AD
- Beyond the Headlines: Dr. Jonathan Silverberg Reviews Maintenance Data on Rademikibart From a Pivotal Trial in Chinahttps://practicaldermatology.com/news/beyond-the-headlines-dr-jonathan-silverberg-reviews-maintenance-data-on-rademikibart-from-a-pivotal-trial-in-china/2462152/DermWire recently reported positive topline results from a 52-week maintenance study of rademikibart in people with atopic dermatitis (AD). At